<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00272415</url>
  </required_header>
  <id_info>
    <org_study_id>IPC-06-2004</org_study_id>
    <secondary_id>INO4136g</secondary_id>
    <nct_id>NCT00272415</nct_id>
  </id_info>
  <brief_title>A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma</brief_title>
  <official_title>A Phase Ib, Open-Label, Multicenter Trial of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate the Tolerability, Safety, and Pharmacokinetics in Subjects With Newly-Diagnosed or Recurrent Unresectable Stage III or Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, non-randomized, multicenter study in adults, aged eighteen
      (18) or older, with newly-diagnosed or recurrent unresectable Stage III or Stage IV melanoma.
      A maximum of 18 subjects will be enrolled in Stage 1 of this study. (Stage 1 completed
      enrollment in June 2006.) A maximum of 39 subjects will be enrolled in Stage 2 of this study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2005</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) or recommended Phase II dose of INO-1001 to be used in combination with TMZ</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile of intravenous INO-1001</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of combined therapy with oral temozolomide (TMZ) and intravenous INO-1001</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of repeat dosing</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) activity of intravenous INO-1001</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INO-1001</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven malignant melanoma with metastasis that is unresectable Stage III or
             Stage IV. Subjects with recurrent melanoma that is unresectable are also eligible

          -  Measurable indicator metastases

          -  Age 18 years or older

          -  ECOG status 0-2

          -  An interval at the time of enrollment of at least: a) 2 weeks since surgical resection
             (if conducted); b) 4 weeks since prior radiotherapy or chemotherapy, and c) 6 weeks
             since chemotherapy with a nitrosourea

          -  Hematocrit &gt; 29%, ANC &gt; 1500 cells/ul, platelets &gt; 100,000 cells/ul

          -  Serum creatinine within the laboratory's upper limit of normal

          -  Serum AST and ALT â‰¤ 1.5 x the laboratory's upper limit of normal

          -  Subject signed informed consent prior to subject entry

        Exclusion Criteria:

          -  Female patients who are pregnant or breast-feeding. Women of childbearing potential
             must have a negative serum or urine pregnancy test within 72 hours prior to
             administration of each cycle of the study drug regimen.

          -  Subjects of childbearing potential who are not willing or able to use an effective
             method of contraception, consisting of at least one-barrier method (e.g., condom and
             diaphragm), for the duration of the study and for at least 3 months after completing
             the treatment.

          -  Subjects previously treated with DTIC or TMZ

          -  Symptomatic central nervous metastases

          -  Concurrent severe and/or uncontrolled medical disease that could compromise
             participation in the study.

          -  Confirmed diagnosis of hepatitis or HIV infection

          -  Any medical, psychiatric, or social problem that might interfere with the performance,
             completion, and/or interpretation of the trial

          -  Patients who have had any surgery within two weeks prior to enrollment in this study,
             or who have not recovered from the side effects of this or any other therapy

          -  Patients unwilling to comply with the protocol or who in the judgment of the Principal
             Investigator are unable to abide by the rules of the protocol

          -  Subjects who have received a potent CYP3A4 inhibitor or inducer orally or parenterally
             within approximately 14 days prior to enrollment

          -  Subjects who have received amiodarone within 30 days of study drug administration

          -  History of hypersensitivity reaction to more than three (3) drugs or to mannitol

          -  Patients who have received any investigational study agent within 30 days of Day 1 of
             Cycle 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Low, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2006</study_first_submitted>
  <study_first_submitted_qc>January 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2006</study_first_posted>
  <last_update_submitted>March 9, 2009</last_update_submitted>
  <last_update_submitted_qc>March 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Clinical Trials Posting Group</name_title>
    <organization>Genentech, Inc.</organization>
  </responsible_party>
  <keyword>INO4136g</keyword>
  <keyword>inotek</keyword>
  <keyword>Parp</keyword>
  <keyword>Temodar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

